Immunovant Inc (IMVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 521,870 | 598,912 | 713,971 | 374,685 | 472,941 |
| Receivables | 1,970 | 1,936 | 2,084 | 2,224 | 1,876 |
| TOTAL | $573,546 | $651,763 | $767,760 | $412,541 | $507,372 |
| Non-Current Assets | |||||
| PPE Net | 632 | 737 | 844 | 752 | 671 |
| Other Non-Current Assets | 8,781 | 8,940 | 7,618 | 7,639 | 7,664 |
| TOTAL | $9,413 | $9,677 | $8,462 | $8,391 | $8,335 |
| Total Assets | $582,959 | $661,440 | $776,222 | $420,932 | $515,707 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 6,916 | 7,843 | 17,656 | 19,816 | 20,727 |
| Accrued Expenses | 56,338 | 45,057 | 51,119 | 48,476 | 45,879 |
| TOTAL | $63,254 | $52,900 | $68,775 | $68,315 | $66,653 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $63,254 | $52,900 | $68,775 | $68,315 | $66,653 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 175,277 | 174,317 | 170,923 | 169,861 | 146,785 |
| Common Shares | 17 | 16 | 16 | 14 | 14 |
| Retained earnings | -1,486,638 | -1,360,136 | -1,239,523 | -1,133,074 | -1,021,952 |
| Other shareholders' equity | 1,450 | 1,737 | 1,459 | 2,479 | 1,910 |
| TOTAL | $519,705 | $608,540 | $707,447 | $352,617 | $449,054 |
| Total Liabilities And Equity | $582,959 | $661,440 | $776,222 | $420,932 | $515,707 |